» Articles » PMID: 10330296

Regulatory Th2-type T Cell Lines Against Insulin and GAD Peptides Derived from Orally- and Nasally-treated NOD Mice Suppress Diabetes

Overview
Journal J Autoimmun
Date 1999 May 20
PMID 10330296
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Non-obese diabetic (NOD) mice spontaneously develop diabetes. Ourselves and others have previously shown that oral and nasal administration of insulin or glutamic acid decarboxylase (GAD) suppresses development of diabetes in the NOD mouse and that this suppression appears secondary to the generation of regulatory T cells that act by secreting anti-inflammatory cytokines such as IL-4 and TGF-beta. In the present study, we analysed cytokine patterns associated with mucosal administration of insulin B-chain, B-chain peptide 10-24 and GAD peptide 524-543 and derived lines and clones from mucosally-treated animals. Mice were fed five times (400-600 microg/feed) or nasally-treated three times (60 microg/application), and 2 days after the last treatment were immunized in the footpad with the mucosally administered antigen in CFA. Primary immune responses in the popliteal lymph node were measured 10 days after immunization and lines and clones were then established from the primary cultures. There was significantly less IFN-gamma production in mucosally-treated mice associated with increased production of IL-10 and TGF-beta. The nature of the antigen appeared to determine cytokine production as the B-chain given either orally or nasally primed for TGF-beta responses, whereas mucosally administered B-chain peptide 10-24 primed for IL-10. T cell clones, established from draining lymph nodes of fed or nasally-treated animals, secreted IL-4, IL-10 and TGF-beta whereas those from non-fed mice secreted IL-2 and IFN-gamma. Transfer of Th1 lines with splenocytes from diabetic NOD mice into NOD or NOD/SCID animals accelerated diabetes, whereas transfer of Th2 lines suppressed the development of diabetes. Our results further support a role for Th2-type cells in the regulation of diabetes in NOD mice.

Citing Articles

Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.

Seefeld M, Templeton E, Lehtinen J, Sinclair N, Yadav D, Hartwell B Front Immunol. 2024; 15:1419527.

PMID: 39286244 PMC: 11403286. DOI: 10.3389/fimmu.2024.1419527.


Type 1 diabetes mellitus and its oral tolerance therapy.

Mao R, Chen Y, Zhang J, Chang X, Wang Y World J Diabetes. 2020; 11(10):400-415.

PMID: 33133388 PMC: 7582116. DOI: 10.4239/wjd.v11.i10.400.


Interleukin-4 Supports the Suppressive Immune Responses Elicited by Regulatory T Cells.

Yang W, Hwang Y, Chen Y, Liu C, Shen C, Hong W Front Immunol. 2017; 8:1508.

PMID: 29184551 PMC: 5694475. DOI: 10.3389/fimmu.2017.01508.


Antigen-specific therapeutic approaches in Type 1 diabetes.

Clemente-Casares X, Tsai S, Huang C, Santamaria P Cold Spring Harb Perspect Med. 2012; 2(2):a007773.

PMID: 22355799 PMC: 3281592. DOI: 10.1101/cshperspect.a007773.


T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Babad J, Geliebter A, DiLorenzo T Immunology. 2010; 131(4):459-65.

PMID: 21039471 PMC: 2999797. DOI: 10.1111/j.1365-2567.2010.03362.x.